Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 7Completed 6Unknown 2Terminated 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 2Dermatologic 2Thoracic 1Sarcoma 1Plasma cell 1Breast 1

Conditions

Melanoma 2Skin Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Autoimmune Diseases 1

Interventions

pembrolizumab 58Ipilimumab 53Cyclophosphamide 53Nivolumab 45aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 19dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11spartalizumab 10Filgrastim 10Dacarbazine 10cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Immunotherapy × Dermatologic × Clear all
NCT03370861 2024-09-05

MINING

Washington University School of Medicine

Terminated
54 enrolled
Dermatologic

Autoimmune Diseases, Carcinoma, Basal Cell, Melanoma, Skin Neoplasms, Carcinoma, Merkel Cell

NCT02054520 2023-04-18

Immunotherapy Study for Patients With Stage IV Melanoma

Lumos Pharma

Phase 2 Terminated
47 enrolled 16 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡